gefitinib has been researched along with m475271 in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (m475271) | Trials (m475271) | Recent Studies (post-2010) (m475271) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 9 | 0 | 7 |
| Protein | Taxonomy | gefitinib (IC50) | m475271 (IC50) |
|---|---|---|---|
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | 0.01 | |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | 0.2721 | |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | 0.01 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.406 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Das, D; Hong, J | 1 |
1 review(s) available for gefitinib and m475271
| Article | Year |
|---|---|
Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.
Topics: Animals; Antineoplastic Agents; Chemistry Techniques, Synthetic; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2019 |